Bausch Health Companies INC. (BHC) — SEC Filings

Overview

Bausch Health Companies INC. (BHC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: Bausch Health Companies Inc. filed an 8-K on December 29, 2025, reporting on events that occurred on December 26, 2025. The filing indicates the entry into a material definitive agreement and the creation of a direct financial obligation. The company, formerly known as Valeant Pharmaceuticals Intern

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 2 bullish, 44 neutral. The dominant filing sentiment for Bausch Health Companies INC. is neutral.

Filing Type Overview

Bausch Health Companies INC. (BHC) has filed 30 8-K, 6 10-Q, 3 DEF 14A, 1 DEFA14A, 2 10-K, 1 SC 13G, 2 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (46)

• Bausch Health Files 8-K on Definitive Agreement — 8-K · Dec 29, 2025 Risk: medium
  Bausch Health Companies Inc. filed an 8-K on December 29, 2025, reporting on events that occurred on December 26, 2025. The filing indicates the entry into a ma
• 8-K Filing — 8-K · Dec 23, 2025
• Bausch Health Files 8-K — 8-K · Dec 12, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on December 12, 2025, reporting other events and financial statements. The company, formerly known as Valeant Pharmace
• Bausch Health Files 8-K: Other Events & Financials — 8-K · Dec 9, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on December 9, 2025, reporting an event that occurred on December 8, 2025. The filing pertains to 'Other Events' and '
• Bausch Health Files 8-K Report — 8-K · Nov 24, 2025 Risk: low
  On November 24, 2025, Bausch Health Companies Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and
• Bausch Health Swings to Profit, Boosts Sales Amid Debt Restructuring — 10-Q · Oct 30, 2025 Risk: medium
  Bausch Health Companies Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income
• Bausch Health Files 8-K on Financials — 8-K · Oct 29, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Bausch Health Files 8-K on Shareholder Vote Matters — 8-K · Oct 9, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on October 9, 2025, reporting on a submission of matters to a vote of security holders that occurred on October 7, 202
• Bausch Health Files 8-K — 8-K · Sep 11, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on September 11, 2025, reporting other events and financial statements. The company, formerly known as Valeant Pharmac
• Bausch Health Seeks Shareholder Approval for Anti-Takeover Rights Plan — DEF 14A · Aug 27, 2025 Risk: medium
  Bausch Health Companies Inc. (BHC) filed a DEF 14A on August 27, 2025, to seek shareholder ratification of its Amended and Restated Shareholder Rights Plan, ini
• Bausch Health Files 8-K: Agreement Termination, Officer Changes — 8-K · Aug 15, 2025 Risk: medium
  Bausch Health Companies Inc. filed an 8-K on August 15, 2025, reporting the termination of a material definitive agreement and changes in directors and officers
• Bausch Health Sees Q2 Revenue Jump, Product Sales Drive Growth — 10-Q · Jul 31, 2025 Risk: medium
  Bausch Health Companies Inc. reported total revenues for the three months ended June 30, 2025, and 2024, and for the six months ended June 30, 2025, and 2024. T
• Bausch Health Files 8-K on Financials — 8-K · Jul 30, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on July 30, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Bausch Health Files 8-K: Other Events & Financials — 8-K · Jul 29, 2025 Risk: low
  On July 29, 2025, Bausch Health Companies Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
• Bausch Health Files 8-K: Director Changes & Executive Compensation Updates — 8-K · Jul 24, 2025 Risk: low
  On July 22, 2025, Bausch Health Companies Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes t
• Bausch Health Files 8-K on Officer/Director Changes — 8-K · Jul 10, 2025 Risk: medium
  Bausch Health Companies Inc. filed an 8-K on July 10, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointm
• Bausch Health Enters Material Agreement, Creates Financial Obligation — 8-K · Jun 27, 2025 Risk: medium
  On June 26, 2025, Bausch Health Companies Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
• Bausch Health Files 8-K: Corporate Updates — 8-K · Jun 18, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on June 18, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing indicates the company's
• Bausch Health Files 8-K: Corporate Details & History — 8-K · Jun 10, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on June 10, 2025, reporting other events and financial statements. The filing details the company's corporate structur
• Bausch Health Enters Material Definitive Agreement — 8-K · May 21, 2025 Risk: medium
  On May 20, 2025, Bausch Health Companies Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related t
• Bausch Health Announces Executive and Board Changes — 8-K · May 15, 2025 Risk: medium
  On May 9, 2025, Bausch Health Companies Inc. announced changes in its executive team and board of directors. The filing details the departure of certain officer
• Bausch Health Files 8-K on Shareholder Votes — 8-K · May 14, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on May 14, 2025, to report on matters submitted to a vote of its security holders. The filing details the submission o
• Bausch Health Files Q1 2025 10-Q — 10-Q · May 1, 2025 Risk: medium
  Bausch Health Companies Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Valeant Pharmaceuticals International, Inc., is
• Bausch Health Files 8-K on Operations & Financials — 8-K · Apr 30, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on April 30, 2025, reporting on its results of operations and financial condition, and including financial statements
• Bausch Health Files Proxy Materials — DEFA14A · Apr 22, 2025 Risk: low
  Bausch Health Companies Inc. filed a Definitive Additional Materials proxy statement on April 22, 2025. This filing relates to the company's proxy materials, wh
• Bausch Health Files 8-K on Material Agreements — 8-K · Apr 15, 2025 Risk: medium
  Bausch Health Companies Inc. filed an 8-K on April 15, 2025, reporting on events that occurred on April 14, 2025. The filing indicates an entry into a material
• Bausch Health Enters Material Definitive Agreement — 8-K · Apr 9, 2025 Risk: medium
  On April 8, 2025, Bausch Health Companies Inc. entered into a material definitive agreement, which also created a direct financial obligation for the registrant
• DEF 14A Filing — DEF 14A · Apr 2, 2025
• Bausch Health Files 8-K for Financials — 8-K · Mar 25, 2025 Risk: low
  On March 25, 2025, Bausch Health Companies Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
• Bausch Health Files 8-K: Other Events & Exhibits — 8-K · Mar 19, 2025 Risk: low
  On March 19, 2025, Bausch Health Companies Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No sp
• Bausch Health Files 2024 10-K — 10-K · Feb 20, 2025 Risk: medium
  Bausch Health Companies Inc. filed its 2024 10-K on February 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Val
• Bausch Health Files 8-K on Financials — 8-K · Feb 19, 2025 Risk: low
  Bausch Health Companies Inc. filed an 8-K on February 19, 2025, reporting on its results of operations and financial condition. The filing includes financial st
• Bausch Health Enters Material Agreement, Incurs Financial Obligation — 8-K · Nov 1, 2024 Risk: medium
  On November 1, 2024, Bausch Health Companies Inc. filed an 8-K to report the entry into a material definitive agreement and the creation of a direct financial o
• Bausch Health Files Q3 2024 10-Q — 10-Q · Oct 31, 2024 Risk: medium
  Bausch Health Companies Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Valeant Pharmaceuticals International, Inc.
• Bausch Health Files 8-K on Operations and Financials — 8-K · Oct 30, 2024 Risk: low
  Bausch Health Companies Inc. filed an 8-K on October 30, 2024, reporting on its results of operations and financial condition. The filing also includes financia
• SC 13G Filing — SC 13G · Aug 30, 2024
• Icahn Entities Amend Bausch Health Stake Filing — SC 13D/A · Aug 19, 2024 Risk: medium
  Carl C. Icahn, through various entities including Icahn Capital LP and Icahn Enterprises Holdings L.P., has amended their Schedule 13D filing regarding Bausch H
• Bausch Health Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: medium
  Bausch Health Companies Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the company's financial performance and operations during the
• Bausch Health Announces Director Changes and Officer Compensation Updates — 8-K · Jul 19, 2024 Risk: medium
  Bausch Health Companies Inc. announced on July 15, 2024, the departure of director Dr. John T. Paul and the election of new directors, including Dr. Robert L. J
• Bausch Health Files 8-K on Security Holder Votes — 8-K · May 15, 2024 Risk: low
  Bausch Health Companies Inc. filed an 8-K on May 15, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
• Bausch Health Companies Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk:
  Bausch Health Companies Inc. (BHC) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Bausch Health Companies Inc. filed a 10-Q report for the period
• Bausch Health Companies Inc. Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Apr 4, 2024 Risk: low
  Bausch Health Companies Inc. (BHC) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. Bausch Health Companies Inc. filed a Definitive Proxy Statem
• Bausch Health Companies Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024 Risk:
  Bausch Health Companies Inc. (BHC) filed a Annual Report (10-K) with the SEC on February 22, 2024. Bausch Health Companies Inc. filed its 2023 Form 10-K on Febr
• GoldenTree Amends Bausch Health Stake, Passive Investment Noted — SC 13G/A · Feb 13, 2024 Risk: low
  GoldenTree Asset Management LP, a New York-based investment firm, filed an amended Schedule 13G/A on February 13, 2024, indicating a change in their ownership o
• Icahn Amends Bausch Health Stake, Signals Ownership Change — SC 13D/A · Feb 7, 2024
  Carl Icahn and his affiliated entities, including Icahn Capital LP, filed an amendment to their Schedule 13D on February 7, 2024, indicating a change in their b
• Bausch Health Reports Executive Changes, Compensation on Jan 29 — 8-K · Feb 1, 2024
  Bausch Health Companies Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 29, 2024. This filing indicates a change in leadershi

Risk Profile

Risk Assessment: Of BHC's 39 recent filings, 0 were flagged as high-risk, 18 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Bausch Health Companies INC.'s most recent 10-Q filing (Oct 30, 2025):

• Revenue: $7,470M
• Net Income: $223M
• EPS: $0.73
• Debt-to-Equity: -0.13
• Cash Position: $1,308M
• Operating Margin: 17.9%
• Total Assets: $26,824M
• Total Debt: $21,042M

Key Executives

• John Paulson
• Seana Carson
• Thomas J. Appio
• Carl C. Icahn
• Dr. John T. Paul
• Dr. Robert L. Johnson
• Ms. Sarah E. Johnson

Industry Context

Bausch Health operates in the diversified healthcare industry, encompassing pharmaceuticals and medical devices. The sector is characterized by significant R&D investment, stringent regulatory oversight, and competitive pressures from both branded and generic manufacturers. Trends include an aging global population driving demand for treatments, increasing focus on specialty pharmaceuticals, and ongoing consolidation.

Top Tags

financial-reporting (8) · 8-K (7) · corporate-governance (6) · financial-obligation (4) · Pharmaceuticals (4) · material-agreement (4) · 10-Q (4) · shareholder-vote (3) · corporate-filing (3) · company-history (3)

Key Numbers

• Net Income: $223M — Swung from a $170M net loss in 2024 for the nine months ended September 30.
• Product Sales: $7.39B — Increased by 5.7% from $6.99B in the prior year for the nine months ended September 30.
• Operating Income: $1.34B — Increased from $988M in the prior year for the nine months ended September 30.
• Current Long-Term Debt: $579M — Reduced significantly from $2.67B at December 31, 2024.
• Non-Current Long-Term Debt: $20.46B — Increased from $18.94B at December 31, 2024.
• Cash and Cash Equivalents: $1.31B — Increased from $1.18B at December 31, 2024.
• Common Shares Outstanding: 370.5M — As of September 30, 2025, up from 367.8M at December 31, 2024.
• Basic EPS: $0.73 — Improved from $(0.38) in the prior year for the nine months ended September 30.
• SEC File Number: 001-14956 — Identifies the company's filing history with the SEC.
• I.R.S. Employer Identification Number: 98-0448205 — Tax identification number for the company.
• Threshold for 'Acquiring Person': 20% — A person owning 20% or more of voting shares triggers the Rights Plan, unless it's a Permitted Bid.
• Original adoption date of Rights Plan: April 14, 2025 — The date the Board initially adopted the shareholder rights plan.
• Mailing date of proxy materials: August 27, 2025 — The date proxy materials were first mailed to shareholders.
• Date of Special Meeting: October 7, 2025 — Shareholders will vote on the Rights Plan at this virtual meeting.
• Time of Special Meeting: 9:00 A.M. Eastern Time — The scheduled start time for the virtual Special Meeting.

Related Companies

BLCO · PFE · JNJ · MRK

Frequently Asked Questions